NASDAQ:PSNL - Nasdaq - US71535D1063 - Common Stock - Currency: USD
4.715
-0.71 (-13.17%)
The current stock price of PSNL is 4.715 USD. In the past month the price decreased by -23.33%. In the past year, price increased by 268.36%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
DHR | DANAHER CORP | 28.07 | 151.18B | ||
A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
WAT | WATERS CORP | 31.58 | 22.26B | ||
ICLR | ICON PLC | 14.39 | 16.63B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
RVTY | REVVITY INC | 23.23 | 13.85B | ||
AVTR | AVANTOR INC | 17.3 | 11.78B | ||
TEM | TEMPUS AI INC | N/A | 10.72B |
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 223 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
PERSONALIS INC
6600 Dumbarton Circle
Fremont CALIFORNIA 94025 US
CEO: John West
Employees: 224
Company Website: https://www.personalis.com/
Investor Relations: https://investors.personalis.com/
Phone: 16507521300
The current stock price of PSNL is 4.715 USD. The price decreased by -13.17% in the last trading session.
The exchange symbol of PERSONALIS INC is PSNL and it is listed on the Nasdaq exchange.
PSNL stock is listed on the Nasdaq exchange.
12 analysts have analysed PSNL and the average price target is 7.6 USD. This implies a price increase of 61.17% is expected in the next year compared to the current price of 4.715. Check the PERSONALIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PERSONALIS INC (PSNL) has a market capitalization of 399.31M USD. This makes PSNL a Small Cap stock.
PERSONALIS INC (PSNL) currently has 224 employees.
PERSONALIS INC (PSNL) has a support level at 4.71 and a resistance level at 5.13. Check the full technical report for a detailed analysis of PSNL support and resistance levels.
The Revenue of PERSONALIS INC (PSNL) is expected to grow by 13.84% in the next year. Check the estimates tab for more information on the PSNL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PSNL does not pay a dividend.
PERSONALIS INC (PSNL) will report earnings on 2025-02-27, after the market close.
PERSONALIS INC (PSNL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.68).
The outstanding short interest for PERSONALIS INC (PSNL) is 6.5% of its float. Check the ownership tab for more information on the PSNL short interest.
ChartMill assigns a technical rating of 6 / 10 to PSNL. When comparing the yearly performance of all stocks, PSNL is one of the better performing stocks in the market, outperforming 98.48% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to PSNL. While PSNL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months PSNL reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS increased by 25.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -38.12% | ||
ROE | -54.83% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to PSNL. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 30.64% and a revenue growth 13.84% for PSNL